EAM
ACAD icon

EFG Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

EFG Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,748
Closed -$1.23M – 188
2024
Q2 		$1.23M Buy
75,748
+364
+0.5% +$5.87K 0.21% 168
2024
Q1 		$1.39M Buy
75,384
+28,405
+60% +$704K 0.24% 166
2023
Q4 		$1.47M Buy
46,979
+7,098
+18% +$170K 0.28% 142
2023
Q3 		$830K Buy
+39,881
New +$1.08M 0.2% 157

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

EFG Asset Management's ACAD Position: Q3 2024 in Review

EFG Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 75,748 shares — an estimated $1.23M sold.

EFG Asset Management first reported a position in ACAD in Q3 2023 and held it in 4 quarters. The position peaked at $1.47M in Q4 2023. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • EFG Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • EFG Asset Management sold 75,748 Acadia Pharmaceuticals shares in Q3 2024, an estimated $1.23M.
  • EFG Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • EFG Asset Management's Acadia Pharmaceuticals position peaked at $1.47M in Q4 2023.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on EFG Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.